Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan.

Hirotaka Shimizu Katsuhiro Arai Ichiro Takeuchi Kei Minowa Kenji HosoiMasamichi SatoItsuhiro OkaYoichiro KaburakiToshiaki Shimizu

Published in: Pediatric gastroenterology, hepatology & nutrition (2021)

IFX is relatively safe and effective for children with UC. Clinical remission at week 30 was associated with long-term durability of colectomy-free IFX treatment. However, approximately two-thirds of the patients were unable to continue IFX therapy because of primary nonresponse, sLOR, IRs, and other side effects.

Keyphrases

ulcerative colitis
end stage renal disease
young adults
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
emergency department
clinical trial
rheumatoid arthritis
big data
bone marrow
smoking cessation
double blind
placebo controlled